NCT04703673 is a clinical trial of Cineole in Rhinosinusitis Acute, sponsored by Engelhard Arzneimittel GmbH & Co.KG.

Who is sponsoring NCT04703673?

NCT04703673 is sponsored by Engelhard Arzneimittel GmbH & Co.KG.

What drugs are being tested in NCT04703673?

Interventions in NCT04703673: Cineole, Nasal Decongestant.

What condition does NCT04703673 study?

NCT04703673 studies Rhinosinusitis Acute, Rhinosinusitis Chronic, Bronchitis.

Is NCT04703673 still recruiting?

NCT04703673 is currently completed. Last updated 12 October 2022.

Last reviewed 2022-10-12 · How we verify

NCT04703673

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sinolpan® Pharmacy Non-interventional Study - Quality of Live

Completed Last updated 12 October 2022

What this trial tests

trial testing Cineole in Rhinosinusitis Acute in 350 participants. Completed in 30 April 2022.

Timeline

8 January 2021

Primary endpoint
30 April 2022

30 April 2022

Quick facts

Lead sponsor	Engelhard Arzneimittel GmbH & Co.KG
Status	Completed
Study type	OBSERVATIONAL
Enrollment	350
Start date	8 January 2021
Primary completion	30 April 2022
Estimated completion	30 April 2022
Sites	1 location across Germany

Drugs / interventions tested

Cineole (Cineole) — full drug profile →
Nasal Decongestant — full drug profile →

Conditions studied

Rhinosinusitis Acute — all drugs for Rhinosinusitis Acute →
Rhinosinusitis Chronic — all drugs for Rhinosinusitis Chronic →
Bronchitis — all drugs for Bronchitis →

Sponsor

Engelhard Arzneimittel GmbH & Co.KG — full company profile →

Who can join

18 and older, any sex, with Rhinosinusitis Acute or Rhinosinusitis Chronic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This non-interventional study investigates the Quality of Life of patients suffering from rhinosinusitis. Patients who seek advice in a pharmacy and choose to intake Sinolpan® or Sinolpan® forte or to use nasally applied α-sympathomimetics can participate in this anonymous patient survey.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Rhinosinusitis Treatment with Cineole: Patient-Reported Quality of Life Improvements from a Non-Interventional, Pharmacy-Based Survey.
Werkhäuser N, Pieper-Fürst U, Sahin H, Claas A, et al · · 2023 · cited 3× · PMID 37367732 · DOI 10.3390/medicines10060037

Verify or expand the search:

Other recruiting trials for Rhinosinusitis Acute

Currently open trials in the same condition.

NCT06901297 — The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04703673 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Engelhard Arzneimittel GmbH & Co.KG
Last refreshed: 12 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04703673.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing